Emcure Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Outcome of the meeting of the Board of Directors considering requests for re-classification from the Promoter and Promoter Group category to Public category'.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals' Board, at its meeting on June 21, 2025, approved requests from 29 members of the Promoter and Promoter Group to be reclassified as 'Public.' The applicants include individuals, trusts, LLPs, and private limited companies such as Heritage Pharma Holdings Inc., Thapar Ventures, and several Thapar family trusts. Importantly, the filing states that none of these 29 entities hold any equity shares of the company. The reclassification is subject to No Objection Certificates from BSE and NSE, and also requires shareholder approval at the next AGM.
Since the applicants currently hold zero shares in the company, this reclassification has no direct impact on shareholding structure or stock price. It is largely a housekeeping exercise to formally move non-shareholding promoter group entities to the public category, which improves the accuracy of shareholding disclosures.